Regeneron enhances checkpoint therapy with CD28 bispecifics; plus NIH funds Alzheimer’s brain mapping, Genentech and more

BioCentury’s roundup of preclinical news

Regeneron combines CD28 bispecifics with PD-1 mAb
In its latest paper covering anti-CD28 bispecific antibodies, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) showed in Science Translational Medicine that the bispecifics could boost anti-PD-1 efficacy. Bispecifics against CD28 and PSMA, or CD28 and EGFR, synergized with an anti-PD-1 mAb to activate T cells

Read the full 489 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE